FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

The MHRA is working with the manufacturer of the IXCHIQ  vaccine, Valneva. This vaccine was approved by the MHRA in February 2025. There will be no impact on operational issues as this vaccine is not ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

The Chikungunya virus (CHIKV) is found in the subtropical regions of the Americas, Africa, Southeast Asia , India , and the ...

This is a precautionary measure while the MHRA conducts the safety review. Following global reports of serious adverse events ...

To access our most recent research and articles on Covid-19 and Covid-19 vaccines, please visit the NEJM Coronavirus (Covid-19) page. To realize the potential of recently developed Covid-19 ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...